US2008161284A1PendingUtilityA1

Delta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it.

Assignee: SERVIER LABPriority: Oct 11, 2005Filed: Feb 20, 2008Published: Jul 3, 2008
Est. expiryOct 11, 2025(expired)· nominal 20-yr term from priority
A61P 9/06A61P 9/00A61P 9/04A61P 9/10C07D 223/16C07B 2200/13A61K 31/55
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A δ-crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.

Claims

exact text as granted — not AI-modified
1 . A δ-Crystalline form of ivabradine hydrochloride of formula (I): 
       
         
           
           
               
               
           
         
       
     
     
         2 . The δ-Crystalline form of ivabradine hydrochloride of  claim 1  having a powder X-ray diffraction diagram exhibiting peaks at 16.8, 17.9, 19.2, 22.2 and 27.6 deg 2 theta. 
     
     
         3 . The δ-Crystalline form of ivabradine hydrochloride of  claim 1  having a powder X-ray diffraction diagram exhibiting peaks at 4.1, 8.4 and 10.9 deg 2 theta. 
     
     
         4 . A pharmaceutical composition comprising as active ingredient the δ-crystalline form of ivabradine hydrochloride of  claim 1 , in combination with one or more pharmaceutically acceptable, inert, non-toxic carriers. 
     
     
         5 . A method for treating or preventing a condition requiring a bradycardic, such method comprising the step of administering to a living animal body, including a human, a therapeutically effective amount of a δ-crystalline form of ivabradine hydrochloride of  claim 1 . 
     
     
         6 . A method for treating or preventing clinical situations of myocardial ischaemia and/or a condition involving rhythm disturbances, such method comprising the step of administering to a living animal body, including a human, a therapeutically effective amount of the δ-crystalline form of ivabradine hydrochloride of  claim 1 . 
     
     
         7 . The method of  claim 6 , wherein the clinical situation of myocardial ischaemia is selected form angina pectoris, myocardial infarct and associated rhythm disturbances. 
     
     
         8 . The method of  claim 6 , wherein the condition involving rhythm disturbances is selected from supraventricular rhythm disturbances and heart failure.

Join the waitlist — get patent alerts

Track US2008161284A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.